Meeting
2018 ASCO Annual Meeting
Carfilzomib and dexamethasone (Kd56) vs bortezomib and dexamethasone (Vd) in relapsed or refractory multiple myeloma (RRMM): Updated overall survival (OS), safety, and subgroup analysis of ENDEAVOR.
Authors
Robert Z. Orlowski
The University of Texas MD Anderson Cancer Center, Houston, TX
Robert Z. Orlowski , Philippe Moreau , Heinz Ludwig , Albert Oriol Rocafiguera , Wee Joo Chng , Hartmut Goldschmidt , Zhao Yang , Amy Kimball , Meletios A. Dimopoulos
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Plasma Cell Dyscrasia
Track
Hematologic Malignancies—Plasma Cell Dyscrasia
Sub Track
Multiple Myeloma
Clinical Trial Registration Number
NCT01568866
Citation
J Clin Oncol 36, 2018 (suppl; abstr 8032)
DOI
10.1200/JCO.2018.36.15_suppl.8032
Abstract #
8032
Poster Bd #
41
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
Efficacy and safety of carfilzomib, dexamethasone, daratumumab (KdD) twice-weekly at 56 mg/m2 and once-weekly at 70 mg/m2 in relapsed or refractory multiple myeloma (RRMM): Cross-study comparison of candor and MMY1001.
First Author: Xavier Leleu
Poster
2016 ASCO Annual Meeting
Adverse event (AE) management in patients (pts) with relapsed and refractory multiple myeloma (RRMM) taking pomalidomide (POM) plus low dose-dexamethasone (LoDEX): A pooled analysis from 3 clinical trials.
First Author: Philippe Moreau
Poster
2015 ASCO Annual Meeting
![MM-007: A phase 3 trial comparing the efficacy and safety of pomalidomide (POM), bortezomib (BORT), and low-dose dexamethasone (LoDEX [PVD]) versus BORT and LoDEX (VD) in subjects with relapsed or refractory multiple myeloma (RRMM).](https://d201v5jt9ylckg.cloudfront.net/156/9331/115230/115230_poster_pv.jpg)
MM-007: A phase 3 trial comparing the efficacy and safety of pomalidomide (POM), bortezomib (BORT), and low-dose dexamethasone (LoDEX [PVD]) versus BORT and LoDEX (VD) in subjects with relapsed or refractory multiple myeloma (RRMM).
First Author: Paul G. Richardson
Poster
2015 ASCO Annual Meeting
Updated results from CHAMPION-1, a phase I/II study investigating weekly carfilzomib with dexamethasone for patients (Pts) with relapsed or refractory multiple myeloma (RRMM).
First Author: James R. Berenson